PD-1-targeted immunotherapy: recent clinical findings

Clin Adv Hematol Oncol. 2012 Oct;10(10):674-5.
No abstract available

MeSH terms

  • Aged
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / immunology
  • Antineoplastic Agents / therapeutic use*
  • B7-H1 Antigen / genetics*
  • B7-H1 Antigen / immunology
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Clinical Trials as Topic
  • Drug Administration Schedule
  • Female
  • Gene Expression
  • Humans
  • Immunoglobulin G / immunology
  • Immunotherapy*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / mortality
  • Lung Neoplasms / therapy*
  • Middle Aged
  • Molecular Targeted Therapy
  • Nivolumab
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / genetics
  • Programmed Cell Death 1 Receptor / immunology
  • Survival Analysis

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • B7-H1 Antigen
  • CD274 protein, human
  • Immunoglobulin G
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab